메뉴 건너뛰기




Volumn 1281, Issue 1, 2013, Pages 36-50

Cardiovascular disease and glycemic control in type 2 diabetes: Now that the dust is settling from large clinical trials

Author keywords

ACCORD; ADVANCE; Blood pressure; Glucagon like peptide 1; Hypoglycemia; Lipids; Macrovascular disease; Type 2 diabetes; VADT

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

EID: 84875663729     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12044     Document Type: Article
Times cited : (87)

References (64)
  • 1
    • 34247483998 scopus 로고    scopus 로고
    • Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study
    • Fox, C.S., S. Coady, P.D. Sorlie, et al. 2007. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115: 1544-1550.
    • (2007) Circulation , vol.115 , pp. 1544-1550
    • Fox, C.S.1    Coady, S.2    Sorlie, P.D.3
  • 2
    • 0032511566 scopus 로고    scopus 로고
    • UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352
    • UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352: 854-865.
  • 3
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes
    • The ADVANCE Collaborative Group.
    • The ADVANCE Collaborative Group. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N. Engl. J. Med. 358: 2560-2572.
    • (2008) N. Engl. J. Med. , vol.358 , pp. 2560-2572
  • 4
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 Diabetes
    • The Action to Control Cardiovascular Risk in Diabetes Study Group.
    • The Action to Control Cardiovascular Risk in Diabetes Study Group. 2008. Effects of intensive glucose lowering in type 2 Diabetes. N. Engl. J. Med. 358: 2545-2559.
    • (2008) N. Engl. J. Med. , vol.358 , pp. 2545-2559
  • 5
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • VADT Investigators.
    • Duckworth, W., C. Abraira, T. Moritz, et al.; VADT Investigators. 2009. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360: 129-139.
    • (2009) N. Engl. J. Med. , vol.360 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 6
    • 79960959816 scopus 로고    scopus 로고
    • Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials
    • Boussageon, R., T. Bejan-Angoulvant, M. Saadatian-Elahi, et al. 2011. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 343: d4169.
    • (2011) BMJ , vol.343
    • Boussageon, R.1    Bejan-Angoulvant, T.2    Saadatian-Elahi, M.3
  • 7
    • 65649106228 scopus 로고    scopus 로고
    • Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
    • Ray, K.K., S.R. Seshasai, S. Wijesuriya, et al. 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-1772.
    • (2009) Lancet , vol.373 , pp. 1765-1772
    • Ray, K.K.1    Seshasai, S.R.2    Wijesuriya, S.3
  • 8
    • 70349881450 scopus 로고    scopus 로고
    • Intensive glucose control and macrovascular outcomes in type 2 diabetes
    • Control Group.
    • Turnbull, F.M, C. Abraira, R.J. Anderson, et al.; Control Group. 2009. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52: 2288-2298.
    • (2009) Diabetologia , vol.52 , pp. 2288-2298
    • Turnbull, F.M.1    Abraira, C.2    Anderson, R.J.3
  • 9
    • 82755165018 scopus 로고    scopus 로고
    • Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
    • Hemmingsen, B., S.S. Lund, C. Gluud, et al. 2011. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898.
    • (2011) BMJ , vol.343
    • Hemmingsen, B.1    Lund, S.S.2    Gluud, C.3
  • 10
    • 84957415695 scopus 로고    scopus 로고
    • Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
    • Hemmingsen, B., S.S. Lund, C. Gluud, et al. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane. Database Syst. Rev. 6: CD008143.
    • (2011) Cochrane. Database Syst. Rev. , Issue.6
    • Hemmingsen, B.1    Lund, S.S.2    Gluud, C.3
  • 11
    • 0037472879 scopus 로고    scopus 로고
    • Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    • Gaede, P., P. Vedel, N. Larsen, et al. 2003. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348: 383-393.
    • (2003) N. Engl. J. Med. , vol.348 , pp. 383-393
    • Gaede, P.1    Vedel, P.2    Larsen, N.3
  • 12
    • 38949210220 scopus 로고    scopus 로고
    • Effect of a multifactorial intervention on mortality in type 2 diabetes
    • Gaede, P., H. Lund-Andersen, H.H. Parving & O. Pedersen. 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358: 580-591.
    • (2008) N. Engl. J. Med. , vol.358 , pp. 580-591
    • Gaede, P.1    Lund-Andersen, H.2    Parving, H.H.3    Pedersen, O.4
  • 13
    • 77951735232 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure control in type 2 diabetes mellitus
    • ACCORD Study Group.
    • Cushman, W.C., G.W. Evans, R.P. Byington, et al.; ACCORD Study Group. 2010. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1575-1585.
    • (2010) N. Engl. J. Med. , vol.362 , pp. 1575-1585
    • Cushman, W.C.1    Evans, G.W.2    Byington, R.P.3
  • 14
    • 34548420712 scopus 로고    scopus 로고
    • Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
    • ADVANCE Collaborative Group.
    • Patel, A., S. MacMahon, J. Chalmers, et al. ADVANCE Collaborative Group. 2007. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
    • (2007) Lancet , vol.370 , pp. 829-840
    • Patel, A.1    MacMahon, S.2    Chalmers, J.3
  • 15
    • 77954374543 scopus 로고    scopus 로고
    • Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
    • Cooper-DeHoff, R.M., Y. Gong, E.M. Handberg, et al. 2010. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304: 61-68.
    • (2010) JAMA , vol.304 , pp. 61-68
    • Cooper-DeHoff, R.M.1    Gong, Y.2    Handberg, E.M.3
  • 16
    • 79951713554 scopus 로고    scopus 로고
    • Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial
    • VADT Study Group.
    • Anderson, R.J., G.D. Bahn, T.E. Moritz, et al.; VADT Study Group. 2011. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 34: 34-38.
    • (2011) Diabetes Care , vol.34 , pp. 34-38
    • Anderson, R.J.1    Bahn, G.D.2    Moritz, T.E.3
  • 17
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • ACCORD Study Group.
    • Ginsberg, H.N., M.B. Elam, L.C. Lovato, et al.; ACCORD Study Group. 2010. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1563-1574.
    • (2010) N. Engl. J. Med. , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 18
    • 77953069181 scopus 로고    scopus 로고
    • Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    • Epub 2010 Jan 26].
    • Calles-Escandón, J., L.C. Lovato, D.G. Simons-Morton, et al. 2010. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33: 721-727. [Epub 2010 Jan 26].
    • (2010) Diabetes Care , vol.33 , pp. 721-727
    • Calles-Escandón, J.1    Lovato, L.C.2    Simons-Morton, D.G.3
  • 19
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • Holman, R.R., S.K. Paul, M.A. Bethel, et al. 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359: 1577-1589.
    • (2008) N Engl J Med. , vol.359 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3
  • 20
    • 84856255697 scopus 로고    scopus 로고
    • Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes
    • Tandon, N., M.K. Ali & K.M. Narayan. 2012. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 12: 7-22.
    • (2012) Am J Cardiovasc Drugs , vol.12 , pp. 7-22
    • Tandon, N.1    Ali, M.K.2    Narayan, K.M.3
  • 21
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • American Diabetes Association; American College of Cardiology Foundation; American Heart Association.
    • Skyler, J.S., R. Bergenstal, R.O. Bonow, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. 2009. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32: 187-192.
    • (2009) Diabetes Care , vol.32 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 22
    • 71049118192 scopus 로고    scopus 로고
    • Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.
    • Veterans Affairs Diabetes Trial.
    • Reaven, P.D., T.E. Moritz, D.C. Schwenke, et al.; Veterans Affairs Diabetes Trial. 2009. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58: 2642-2648.
    • (2009) Diabetes , vol.58 , pp. 2642-2648
    • Reaven, P.D.1    Moritz, T.E.2    Schwenke, D.C.3
  • 23
    • 79951691814 scopus 로고    scopus 로고
    • Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT)
    • on behalf of the Veterans Affairs Diabetes Trial (VADT).
    • Saremi, A., T.E. Moritz, R.J. Anderson, et al., on behalf of the Veterans Affairs Diabetes Trial (VADT). 2010. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 33: 2642-2647.
    • (2010) Diabetes Care , vol.33 , pp. 2642-2647
    • Saremi, A.1    Moritz, T.E.2    Anderson, R.J.3
  • 24
    • 84855185039 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2012
    • American Diabetes Association.
    • American Diabetes Association. 2012. Standards of medical care in diabetes-2012. Diabetes Care 35(Suppl. 1): S11-S63.
    • (2012) Diabetes Care , vol.35 , Issue.SUPPL. 1
  • 25
    • 77954159481 scopus 로고    scopus 로고
    • Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
    • for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators.
    • Riddle, M.C., W.T. Ambrosius, D.J. Brillon, et al., for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. 2010. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33: 983-990.
    • (2010) Diabetes Care , vol.33 , pp. 983-990
    • Riddle, M.C.1    Ambrosius, W.T.2    Brillon, D.J.3
  • 26
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi, S.E., R.M. Bergenstal, J.B. Buse, et al. 2012. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
    • (2012) Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 27
    • 78650122448 scopus 로고    scopus 로고
    • Defining and achieving treatment success in patients with type 2 diabetes mellitus
    • Stolar, M.W. 2010. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo. Clin. Proc. 85(12 Suppl): S50-S59.
    • (2010) Mayo. Clin. Proc. , vol.85 , Issue.12 SUPPL
    • Stolar, M.W.1
  • 28
    • 33646422782 scopus 로고    scopus 로고
    • Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
    • Evans, J.M., S.A. Ogston, A. Emslie-Smith & A.D. Morris. 2006. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49: 930-936.
    • (2006) Diabetologia , vol.49 , pp. 930-936
    • Evans, J.M.1    Ogston, S.A.2    Emslie-Smith, A.3    Morris, A.D.4
  • 29
    • 0141989681 scopus 로고    scopus 로고
    • Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA)
    • Meier, J.J., S. Deifuss, A. Klamann, et al. 2003. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp. Clin. Endocrinol. Diabetes 111: 344-350.
    • (2003) Exp. Clin. Endocrinol. Diabetes , vol.111 , pp. 344-350
    • Meier, J.J.1    Deifuss, S.2    Klamann, A.3
  • 30
    • 77955285732 scopus 로고    scopus 로고
    • Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    • Nissen, S.E. & K. Wolski. 2010. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170: 1191-1201.
    • (2010) Arch. Intern. Med. , vol.170 , pp. 1191-1201
    • Nissen, S.E.1    Wolski, K.2
  • 31
    • 79953203593 scopus 로고    scopus 로고
    • Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
    • Loke, Y.K., C.S. Kwok & S. Singh. 2011. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309.
    • (2011) BMJ , vol.342
    • Loke, Y.K.1    Kwok, C.S.2    Singh, S.3
  • 32
    • 34548590934 scopus 로고    scopus 로고
    • Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials
    • Lincoff, A.M., K. Wolski, S.J. Nicholls & S.E. Nissen. 2007. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 298: 1180-1188.
    • (2007) JAMA , vol.298 , pp. 1180-1188
    • Lincoff, A.M.1    Wolski, K.2    Nicholls, S.J.3    Nissen, S.E.4
  • 33
    • 0041322547 scopus 로고    scopus 로고
    • Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study
    • Winkler, K., T. Konrad, S. Füllert, et al. 2003. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26: 2588-2594.
    • (2003) Diabetes Care , vol.26 , pp. 2588-2594
    • Winkler, K.1    Konrad, T.2    Füllert, S.3
  • 34
    • 20444495375 scopus 로고    scopus 로고
    • Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study
    • Pfützner, A., N. Marx, G. Lübben, et al. 2005. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45: 1925-1931.
    • (2005) J. Am. Coll. Cardiol. , vol.45 , pp. 1925-1931
    • Pfützner, A.1    Marx, N.2    Lübben, G.3
  • 35
    • 33745834319 scopus 로고    scopus 로고
    • Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
    • Kadowaki, T., T. Yamauchi, N. Kubota, et al. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116: 1784-1792.
    • (2006) J. Clin. Invest. , vol.116 , pp. 1784-1792
    • Kadowaki, T.1    Yamauchi, T.2    Kubota, N.3
  • 36
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study
    • PROactive investigators.
    • Dormandy, J.A., B. Charbonnel, D.J. Eckland, et al.; PROactive investigators. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet 366: 1279-1289.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 37
    • 53349153475 scopus 로고    scopus 로고
    • Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
    • Mannucci, E., M. Monami, C. Lamanna, et al. 2008. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 10: 1221-1238.
    • (2008) Diabetes Obes. Metab. , vol.10 , pp. 1221-1238
    • Mannucci, E.1    Monami, M.2    Lamanna, C.3
  • 38
    • 77958529709 scopus 로고    scopus 로고
    • Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?
    • Schernthaner, G. & R.J. Chilton. 2010. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes. Metab. 12: 1023-1035.
    • (2010) Diabetes Obes. Metab. , vol.12 , pp. 1023-1035
    • Schernthaner, G.1    Chilton, R.J.2
  • 39
    • 33847675510 scopus 로고    scopus 로고
    • The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study
    • PROactive Investigators.
    • Erdmann, E., J.A. Dormandy, B. Charbonnel, et al.; PROactive Investigators. 2007. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49: 1772-1780.
    • (2007) J. Am. Coll. Cardiol. , vol.49 , pp. 1772-1780
    • Erdmann, E.1    Dormandy, J.A.2    Charbonnel, B.3
  • 40
    • 33746218171 scopus 로고    scopus 로고
    • Is insulin resistance atherogenic? Possible mechanisms
    • De Fronzo, R.A. 2006. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl. 7: 11-15.
    • (2006) Atheroscler Suppl. , vol.7 , pp. 11-15
    • De Fronzo, R.A.1
  • 41
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group.
    • UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 43
    • 79955397107 scopus 로고    scopus 로고
    • Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies
    • Giorgino, F., A. Leonardini, A. Natalicchio & L. Laviola. 2011. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J. Endocrinol. Invest. 34: 69-77.
    • (2011) J. Endocrinol. Invest. , vol.34 , pp. 69-77
    • Giorgino, F.1    Leonardini, A.2    Natalicchio, A.3    Laviola, L.4
  • 44
    • 66249138889 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 and myocardial protection: more than glycemic control
    • Fields, A.V., B. Patterson, A.A. Karnik & R.P. Shannon. 2009. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin. Cardiol. 32: 236-243.
    • (2009) Clin. Cardiol. , vol.32 , pp. 236-243
    • Fields, A.V.1    Patterson, B.2    Karnik, A.A.3    Shannon, R.P.4
  • 45
    • 2942668372 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
    • Gutzwiller, J.P., S. Tschopp, A. Bock, et al. 2004. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89: 3055-3061.
    • (2004) J. Clin. Endocrinol. Metab. , vol.89 , pp. 3055-3061
    • Gutzwiller, J.P.1    Tschopp, S.2    Bock, A.3
  • 46
    • 53649083746 scopus 로고    scopus 로고
    • The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance
    • Nyström, T. 2008. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 40: 593-606.
    • (2008) Horm. Metab. Res. , vol.40 , pp. 593-606
    • Nyström, T.1
  • 47
    • 50649110233 scopus 로고    scopus 로고
    • Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
    • Courrèges, J.P., T. Vilsbøll, M. Zdravkovic, et al. 2008. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25: 1129-1131.
    • (2008) Diabet. Med. , vol.25 , pp. 1129-1131
    • Courrèges, J.P.1    Vilsbøll, T.2    Zdravkovic, M.3
  • 48
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • Nikolaidis, L.A., S. Mankad, G.G. Sokos, et al. 2004. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965.
    • (2004) Circulation , vol.109 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3
  • 49
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos, G.G., L.A. Nikolaidis, S. Mankad, et al. 2006. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12: 694-699.
    • (2006) J. Card. Fail. , vol.12 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3
  • 50
    • 12144260853 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    • Bose, A.K., M.M. Mocanu, R.D. Carr, et al. 2005. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151.
    • (2005) Diabetes , vol.54 , pp. 146-151
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3
  • 51
    • 58949084130 scopus 로고    scopus 로고
    • Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
    • Timmers, L., J.P. Henriques, D.P. de Kleijn, et al. 2009. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53: 501-510.
    • (2009) J. Am. Coll. Cardiol. , vol.53 , pp. 501-510
    • Timmers, L.1    Henriques, J.P.2    de Kleijn, D.P.3
  • 52
    • 64649102619 scopus 로고    scopus 로고
    • GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
    • Noyan-Ashraf, M.H., M.A. Momen, K. Ban, et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
    • (2009) Diabetes , vol.58 , pp. 975-983
    • Noyan-Ashraf, M.H.1    Momen, M.A.2    Ban, K.3
  • 53
    • 84870161013 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway
    • Laviola, L., A. Leonardini, M. Melchiorre, et al. 2012. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology 153: 5770-5781.
    • (2012) Endocrinology , vol.153 , pp. 5770-5781
    • Laviola, L.1    Leonardini, A.2    Melchiorre, M.3
  • 54
    • 84860204551 scopus 로고    scopus 로고
    • Cardiovascular biology of the incretin system
    • Ussher, J.R. & D.J. Drucker. 2012. Cardiovascular biology of the incretin system. Endocr. Rev. 33: 187-215.
    • (2012) Endocr. Rev. , vol.33 , pp. 187-215
    • Ussher, J.R.1    Drucker, D.J.2
  • 55
    • 41849099939 scopus 로고    scopus 로고
    • Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    • Mistry, G.C., A.L. Maes, K.C. Lasseter, et al. 2008. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol. 48: 592-598.
    • (2008) J. Clin. Pharmacol. , vol.48 , pp. 592-598
    • Mistry, G.C.1    Maes, A.L.2    Lasseter, K.C.3
  • 56
    • 33847024333 scopus 로고    scopus 로고
    • Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
    • Scott, R., M. Wu, M. Sanchez & P. Stein. 2007. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J. Clin. Pract. 61: 171-180.
    • (2007) Int. J. Clin. Pract. , vol.61 , pp. 171-180
    • Scott, R.1    Wu, M.2    Sanchez, M.3    Stein, P.4
  • 57
    • 77956069166 scopus 로고    scopus 로고
    • Hypoglycemia, diabetes and cardiovascular events
    • Desouza, C.V., G.B. Bolli & V. Fonseca. 2010. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care 33: 1389-1394.
    • (2010) Diabetes Care , vol.33 , pp. 1389-1394
    • Desouza, C.V.1    Bolli, G.B.2    Fonseca, V.3
  • 58
    • 80052615073 scopus 로고    scopus 로고
    • Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review
    • Noh, R.M., A.J. Graveling & B.M. Frier. 2011. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opin. Pharmacother. 12: 2161-2175.
    • (2011) Expert Opin. Pharmacother. , vol.12 , pp. 2161-2175
    • Noh, R.M.1    Graveling, A.J.2    Frier, B.M.3
  • 59
    • 0032875210 scopus 로고    scopus 로고
    • Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
    • Landstedt-Hallin, L., A. Englund, U. Adamson & P.E. Lins. 1999. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J. Intern. Med. 246: 299-307.
    • (1999) J. Intern. Med. , vol.246 , pp. 299-307
    • Landstedt-Hallin, L.1    Englund, A.2    Adamson, U.3    Lins, P.E.4
  • 60
  • 61
    • 74949117631 scopus 로고    scopus 로고
    • The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
    • doi: 10.1136/bmj.b4909.
    • Bonds, D.E., M.E. Miller, R.M. Bergenstal, et al. 2010. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340: b4909. doi: 10.1136/bmj.b4909.
    • (2010) BMJ , vol.340
    • Bonds, D.E.1    Miller, M.E.2    Bergenstal, R.M.3
  • 62
    • 79952273819 scopus 로고    scopus 로고
    • Long-term effects of intensive glucose lowering on cardiovascular outcomes
    • ACCORD Study Group.
    • Gerstein, H.C., M.E. Miller, S. Genuth, et al.; ACCORD Study Group. 2011. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364: 818-828.
    • (2011) N. Engl. J. Med. , vol.364 , pp. 818-828
    • Gerstein, H.C.1    Miller, M.E.2    Genuth, S.3
  • 63
    • 77957742069 scopus 로고    scopus 로고
    • Severe hypoglycemia and risks of vascular events and death
    • ADVANCE Collaborative Group.
    • Zoungas, S., A. Patel, J. Chalmers, et al.; ADVANCE Collaborative Group. 2010. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363: 1410-1418.
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1410-1418
    • Zoungas, S.1    Patel, A.2    Chalmers, J.3
  • 64
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group.
    • UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
    • (1998) Lancet , vol.352 , pp. 854-865


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.